Law360, New York (April 10, 2012, 3:48 PM ET) -- Amgen Inc. has acquired KAI Pharmaceuticals Inc., which is developing a drug to combat kidney disease, from its venture capital backers for $315 million, the California-based biotech company said Tuesday.
Amgen said it will acquire San Francisco-based KAI in an all-cash transaction.
Under the terms of the agreement, Amgen will provide a loan to enable the third phase of clinical development for KAI's leading drug candidate KAI-4169, which treats secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis.
In return, Amgen will acquire...
Sullivan Aids Amgen On $315M Kidney Drugmaker Buy
To view the full article, take a free trial now.
